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ABSTRACT The aim of this study was to evaluate zinc gluconate as a treatment option in 
patients with symptomatic migratory glossitis (MG). Using simple random sampling, 28 
non-psoriatic patients with symptomatic MG were divided into a test and control group. 
The test group took 20 mg/day of chelated zinc gluconate for one month, and was put on 
a diet rich in zinc. The control group was only put on a diet rich in zinc. Changes in the size 
of red atrophied areas (width and length) and the intensity of symptoms were evaluated as 
primary and secondary outcomes, respectively, at baseline, after therapy, and one month 
later. In the test group, the mean value of the red atrophy area width and length displayed 
some significant reduction as a primary outcome. There were no significant changes in the 
size of red patches in the control group. Secondary outcome showed that the intensity of 
subjective symptoms in the test group significantly decreased (P=0.042) compared with 
controls. The filiform papillae had partially or completely regenerated in 85.7% of cases 
in the test group and in 23.1% of the controls (P=0.001). Red patches with raised keratotic 
rims may have healed spontaneously and reappeared in constantly changing patterns that 
are typical for MG. This phenomenon was not observed in patients supplemented with 
zinc, and new atrophy areas occurred in only one case. Low-dose zinc gluconate supple-
mentation may have a positive therapeutic effect on tongue epithelium regeneration and 
symptomatology in patients with MG. 
KEY WORDS: zinc, zinc supplementation, migratory glossitis, geographic tongue, con-
trolled clinical trials
INTRODUCTION
Benign migratory glossitis (MG) is an obscure con-
dition, considered to be immune-mediated and as-
sociated with small to extensive areas of atrophy of 
the filiform papillae of the tongue with preservation 
of the fungiform papillae that individually regenerate 
in time, with a degree of hyperplasia of the filiform 
papillae and keratosis and fibrosis of their ends that 
give the borders of the recovering lesion a white halo, 
which may also appear yellow from the entrapment 
of food and bacteria in the now “shaggy” ends of the 
filiform papillae. It can be symptomatic, but likely 
due to the loss of the filiform papillae and atrophy 
of the dorsal tongue surface and resultant increased 
sensitivity to strongly favored foods and agents such 
as peppermint (in toothpaste), chili and alcohol (1-
6). Prevalence in the general population fluctuates 
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within the 1-2.5% range (2-6). The histopathology 
demonstrates Munro’s microabscess (collections of 
neutrophils), also seen in classic psoriasis of the skin, 
hence the hypothesis that these two conditions may 
be associated (5,7-10). Except with fissured tongue 
(4,5) this condition may also coexist with a heightened 
level of IgE, atopic dermatitis, and asthma (11). Altaee 
(12) reports a decreased level of zinc concentration 
in saliva of individuals with MG, albeit without any 
significant difference in respect to the control group. 
A lower zinc concentration in serum was reported in 
a substantial number of individuals who suffer from 
tongue sensitivity and who are unresponsive to ad-
ministered treatment (13). The positive therapeutic 
influence of zinc was also confirmed in treatment of 
burning mouth syndrome (BMS) (14) and dysgeusia 
(15).
Abe et al. (16) report a positive effect of cyclospo-
rine on persistent MG. Zinc sulfate has been speci-
fied as one possible therapeutic approach in treating 
MG (17). MG presents as an enigmatic lesion due to 
its varied etiologies, thereby presenting a treatment 
dilemma (18,19). A review of the literature points to a 
scarcity of evidence about the therapeutic effects of 
zinc in patients with MG, especially when not associ-
ated with psoriasis. The aim of this paper was to test 
the effect of low-dose zinc gluconate replacement 
therapy on tongue epithelium regeneration and 
symptoms in non-psoriatic patients with MG.
PATIENTS AND METHODS
Patients
This was a single-blind controlled clinical study 
with simple randomization. Eligible participants were 
all adults aged 18 year or above with MG. The diag-
nosis was established by an oral medicine special-
ist based on clearly defined criteria: presence of red 
atrophy areas of the filiform papillae with distinctly 
delineated whitish healthy papillae. Exclusion criteria 
were psoriasis (medical history and careful clinical 
morphologic evaluation of skin features due to lack 
of clear diagnostic criteria for psoriasis) (20), anemia, 
B12 or folic acid deficiency (confirmed through a com-
plete blood analysis not older than three months), 
oral candidiasis (negative tongue swab), pregnancy, 
and indicators of localized irritations (dental caries-
affected teeth, sharp teeth edges, dental calculus, 
faulty dental fillings, and faulty prosthetic proce-
dures). A total of 47 non-psoriatic patients with MG 
visited the Oral Medicine Section at Dental Clinic of 
in the period between November 2013 and Jun 2015. 
The study was conducted in 28 patients with symp-
tomatic MG (20 women and 8 men, age range 19-79 
years, mean age 31.13 years). Changes in the size of 
red atrophied areas (width and length) and the in-
tensity of symptoms were evaluated as primary and 
secondary outcomes, respectively. With the use of 
a calibrated periodontal probe, atrophy area length 
(AAL) and atrophy area width (AAW) were measured 
to determinate the size of the diagnosed red atrophic 
patch. In case of irregularly shaped lesions, their larg-
est diameters were measured (Figure 1 and Figure 2). 
Seven days after the diagnosis was made and atrophy 
Figure 1. AAL: atrophy area length; AAW atrophy area 
width. Figure 2. Measurement procedure.
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areas were determined, patients attended a control 
checkup in order to exclude those with constantly 
changing patterns of the red patches with raised ker-
atotic rims. Only those patients who presented with 
atrophic patches bounded with circinate lines that 
remained constant at the control checkup were in-
cluded during the study evaluation process. The size 
of the two largest atrophic patches per patient (most 
patients had one or two patches) was monitored at 
baseline and after the therapy. In the interest of more 
precise therapy effect monitoring, atrophy areas were 
displayed on the schematically presented tongue 
dorsal surface. Intensity of the discomfort, such as 
burning tongue sensation and sensitive tongue, were 
Figure 3. Flow diagram of zinc gluconate supplementation with diet rich in zinc compared with only diet rich in zinc. The 
diagram includes information on the excluded participants.







Age (mean and range) 35.7 (19-79) 26.5 (19-62)
P>0.05
Men 3 (10.7) 5 (17.8)
Women 11 (39.3) 9 (32.1)
Blood glucose
Normal value 4.6-6.2 mmoL/L 13 (46.4) 14 (100)
Above normal value 1 (3.6) 0 (0)
Antihypertensive drugs – yes 2 (7.1) 1 (3.6)
Smoking – yes 3 (10.7) 2 (7.1)
Alcohol yes <14 units per week† 7 (25.0) 5 (17.8)
Serum zinc level (μg/dL) 85.6±0.2 86.4 ±0.2
Mesured oucomes (median)
AAL I (mm) 15.0 12.0 0.497
AAL II (mm) 8.5 9.0 0.711
AAW I (mm) 13.0 5.0 0.83
AAW II (mm) 5.0 6.0 0.447
VAS 3.7 3.0 0.522
AAL: atrophy area length; AAW: atrophy area width; VAS: Visual Analogue Scale; *significance for chi-square, Student t-test and 
Mann-Whitney test; †One unit of alcohol is 10 mL (1 cL) by volume, or 8 g by weight, of pure alcohol. The percentage alcohol 
by volume (% abv) of a drink equals the number of units in one liter of that drink.
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estimated using the Visual Analogue Scale (VAS), 0-10 
(with 1 cm increments, “0” indicated no discomfort, 
“10” unendurable, the worst imaginable discomfort). 
Patients were instructed to select a value on the VAS 
scale which best corresponded to the intensity of 
their symptoms. Using visual examination, the heal-
ing process of atrophy areas was also assessed based 
on the degree of filiform papillae regeneration. Com-
plete regeneration was defined as complete resolu-
tion of red patches. Partial regeneration was defined 
as presenting with fine whitish newly-regenerated 
filiform papillae that protruded slightly above the 
lingual surface at the previously atrophied area. A 
specially designed protocol was included, consisting 
of: socio-demographic variables (sex, age); health risk 
habits (smoking, alcohol use); use of antihypertensive 
drugs, and the single most common provoking fac-
tor that caused subjective symptoms, such as burn-
ing tongue sensation and sensitive tongue. Patients 
gave their written informed consent after familiar-
izing themselves with the procedure. The study was 
approved by the Dental Clinic Ethics Committee (No. 
01-5/4-2014) and was conducted in accordance with 
the code of ethics of the Helsinki Declaration of 1975, 
as revised in 2008.
Pre-specified outcome measure 
Before randomization, blood samples for the anal-
ysis were successfully collected from all participants 
with symptomatic MG. Serum zinc concentration was 
measured using flame atomic absorption spectro-
photometry, which is a common analytic method for 
measuring zinc in biological samples (Perkin Elmer 
HGA 460, Germany; reference range 65-110 μg/dL).
Randomization and treatment
All patients diagnosed with symptomatic MG 
were allocated to two groups in the order of their 
arrival through a simple random sampling method 
by using a free web service: “Research Randomizer” 
available from http://www.randomizer.org (Social 
Psychology Network, Lancaster, Pennsylvania, USA). 
Of the 28 subjects with the presence of symptom-
atic MG, 27 returned for a follow-up examination af-
ter one month and were included in the process of 
data analysis (Figure 3). The test group consisted of 
14 patients who consumed 20 mg/day of chelated 
zinc gluconate (equivalent to about 2.8 mg/day of 
elemental zinc) over a period of 30 days, divided 
into two dosages, in the form of a commercial di-
etary supplement “Chelated Zinc” (Natural wealth®, 
New York, USA). Since 2012, only this zinc gluconate 
Table 2. Distribution of the single most provok-
ing factor that caused soreness among subjects 
with migratory glossitis




Sour food 9 (32.1)
Toothpaste 8 (28.6)
Piquant food 4 (14.3)
Spicy food 1 (3.6)
Tomatoes 1 (3.6)
Nuts 1 (3.6)
Orange juice 1 (3.6)
Chocolate cream 1 (3.6)
Mouthwash product 1 (3.6)








Control group n=13 P significance*
mean ± SD mean ± SD Test group Control group
AAL I 
(mm)
Baseline 20.14±14.07 17.29±17.58 P=0.31 P=0.17
After 15.29±13.08 14.43±19.31
AAL II (mm) Baseline 11.00±6.16 9.60±6.95 P=0.049 P=0.28
After 5.50±4.43 12.00±10.10
AAW I (mm) Baseline 16.86±12.66 12.57±16.92 P=0.02 P=0.89
After 8.14±4.05 12.29±17.63
AAW II (mm) Baseline 5.00±1.63 5.80±1.30 P=0.28 P=0.59
After 4.00±2.70 7.80±6.94
SD: Standard Deviation; AAL I: first atrophy area length; AAL II: second atrophy area length; AAW I: first atrophy 
area width; AAW II: second atrophy area width; *Wilcoxon test; P<0.05 was considered statistically significant 
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dietary supplement has been filed in the Registry of 
Dietary Supplements, issued by the Republic of Ser-
bia Ministry of Health. Patients were advised to swal-
low the tablets on an empty stomach, before meals. 
During the same time period, patients were on a 
diet rich in zinc recommended by a nutritionist. The 
control group was composed of the same number of 
patients who only received a the zinc rich diet in the 
same period of time. A nutritionist advised patients 
to take one standard portion of food items with as-
sumed zinc content of 2-5 mg every single day. Food 
items in the patients’ diet with that zinc content were: 
beef (1 average slice), eggs with yolk (2 of average 
size), yogurt (1 cup), pork liver (1 average slice), beans 
(1 cup), dark turkey meat (1 average slice), shrimps (1 
cup), peanuts (quarter of cup), pumpkin seeds (quar-
ter of cup), barley kernel (1 cup), rye kernel (1 cup), 
and button mushrooms – Agaricus bisporus (2 cups) 
(20). Participants received no additional information 
about daily oral care. the date of therapy initiation 
and the date of evaluation one month later were set 
for each patient in both groups. The investigator had 
performed the interview, measurement, and clinical 
examination, at baseline (T1) and after (T2) the treat-
ment, did not have any knowledge at the time as to 
whether the patients were being treated with zinc 
gluconate with a diet rich in zinc or only with a diet 
rich in zinc (single-blind). Patients were asked to re-
evaluate subjective symptoms after therapy (T2) and 
on an additional follow-up one month after cessation 
of therapy (T3) using the VAS scale. 
Statistical analysis
The sample size was calculated based on α=0.05 
and β=0.20; treatment effect size for zinc sulfate 
therapy and placebo were 80% and 15% respectively 
(17). A minimum sample size of 8 subjects for each 
group was obtained. SPSS 17 for Windows for statis-
tical analysis (WinWrap Basic, Nikiski, AK, USA). For 
categorical variables, data were displayed as absolute 
and relative values, and as mean values and measures 
of variability for numerical variables. When evaluat-
ing the variation of values at baseline and after the 
treatment, Student`s t-test, ANOVA, and Wilcoxon 
nonparametric signed-rank test was applied for nu-
meric features and Chi-square test (Yates’ Correction) 
for categorical data. A value of P<0.05 was considered 
statistically significant. 
RESULTS
After simple random sampling, there was no dif-
ference in regards to socio-demographic and health 
risk habits between the groups. Baseline character-
istics of the sample and the single most common 
provoking factor are presented in Table 1 and Table 
2. In four subjects (14.3%), more than two tongue 
areas of atrophy were identified during the first or 
follow-up clinical examination, which were not in-
cluded in the statistical analysis (the two largest le-
sions were selected). During and after the therapy in 
the test group a new (not previously observed) red 
patch occurred in only one case, while in such new 
patches were observed in three patients (23.1%) from 
the control group. A complete absence of subjective 
symptoms after the treatment was reported by four 
individuals from the test group (28.6%), and by none 
from the control group (P=0.122). In six cases (42.9%) 
on zinc therapy and in one control patient (7.7%) a 
complete regeneration of the observed red areas was 
found with no difference (P=0.100; Yates’ Correction). 
The atrophy areas changed either through partial or 
complete regeneration in 12 (85.7%) patients from 
the test group and in three patients (23.1%) from the 
control grup (P=0.001; Yates’ Correction). In the test 
group, there was a significant decrease in the mean 
of the first AAW and second AAL after the treatment 
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Table 4. Mean changes (decrease) and difference within each subject in Visual Analogue Scale (VAS) at base-
line, after treatment, and one month later for test and control groups
Test group n=14 Control group n=13 Test group Control 














VAS 1 4.59±3.29 1,90±2.06* 2.29±2.21* 3.04±1.31 2.49±1.05 2.81±1.10 0.042 0.167
T1-T2 T1-T3 T2-T3 T1-T2 T1-T3 T2-T3 P value T test**
VAS2 2.70±2.04 2.31±1.87 0.39± 0.63 0.56±1.05 0.23±0.56 0.33±0.50 T1-T2 T1-T3 T2-T3
0.029 0.025 0.854
SD: Standard Deviation; VAS1: visual analog scale mean for the group; VAS2 visual analog scale difference within each sub-
jects and presented as mean for the group; *Statistically significantly different from Baseline (T1) (P<0.05), **differences 
between the groups
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(P=0.02 P=0.049, respectively). The mean of the first 
AAL and second AAW also declined after the admin-
istered treatment, albeit without significant differ-
ence. In the control group, we found a decrease in 
mean values of first AAL and AAW and an increase 
of second the AAL and AAW, with no significance 
(Table 3). Table 4 summarizes VAS scores presented 
as mean (VAS1) or difference for each subjects and 
displayed as mean for the group (VAS2) at baseline 
(T1), after treatment (T2), and one month later (T3) 
for the test and control group. In the test patients, a 
statistically significant decrease (P<0.05) in mean VAS 
was observed at T2 (1.90±2.06; mean ± Standard De-
viation) and T3 (2.29±2.21) respectively, in relation to 
T1 (4.59±3.29). In the control patients, no statistically 
significant decreases in mean VAS were observed. A 
different approach to statistical analysis also yielded 
a significant reduction of symptoms after therapy 
(P=0.029) and one month later (P=0.025) in the test 
group compared to controls.
DISCUSSION
As an asymptomatic inflammatory disorder in 
most cases, benign migratory glossitis may present 
similar genetic, histopathological, and clinical fea-
tures as oral psoriasis (21). Although the existence of 
oral psoriasis is disputed, association between pso-
riasis and migratory glossitis or stomatitis has been 
confirmed in previous studies (9,10). Due to similar 
clinical features in benign migratory glossitis and skin 
disease, histological assessment may be needed for 
definitive diagnosis. Due to asymptomatic oral le-
sions, clinicians find it difficult to carry out biopsies for 
histological examination in order to establish defini-
tive diagnosis of oral psoriasis. Detailed patient and 
family history, data for disease recurrence, and care-
ful clinical inspection may be useful in making oral 
diagnosis. Having such a complexion of the tongue 
can induce feelings of anxiety in patients due to sus-
pected malignancy, and that is one of the reasons for 
the increased importance of finding a treatment for 
this condition (22).
Positive effect of MG treatment with local anes-
thetics, corticosteroid therapy, antihistamines, and 
tacrolimus have not yet been thoroughly elucidated 
(18,19). To the best of our knowledge, only one clini-
cal study in the literature reported data on the thera-
peutic effect of zinc sulfate in patients with MG (17), 
which were in agreement with our findings. 
Zinc deficiency can be easily overlooked because 
its clinical features are non-specific. The required 
daily intake of elemental zinc through food varies 
from 6 to 15 mg/day for healthy adults and absorp-
tion amounts to about 20%. The RDA (Recommended 
Dietary Allowance) is 0.2 mg/kg/day for adults (14). 
A chelated form of zinc insures its better utilization 
due to greater absorptive capacity. The conclusions 
of many pharmacokinetic studies of zinc are that zinc 
absorption can be improved by its complexation with 
organic compounds. Furthermore, by comparing or-
ganic forms of zinc (citrate, gluconate) with inorganic 
forms (sulfate, oxide) in terms of absorption and plas-
ma concentrations, it has been found that organic 
forms have better properties (23). On the other hand, 
there was no difference when comparing utilization 
of individual organic forms of zinc (24). Therefore, the 
clinical outcomes of our study are comparable with 
those of the previously mentioned zinc sulfate study 
despite the difference in zinc dose. Vahedi et al. (17) 
used 220 mg of zinc sulfate, which is 50 mg of elemen-
tal zinc, and we used 20 mg of zinc gluconate, which 
is 2.8 mg of elemental zinc, to achieve similar results. 
We tried to achieve the same clinical outcomes using 
a lower zinc dose because we were aware that the 
increase in elemental zinc concentration can change 
the status of trace elements absorbed competitively 
with zinc (Cu, Fe). This was demonstrated in the Ze-
nith Project, where supplementation with zinc glu-
conate at 15 or 30 mg per day increased serum Zn 
levels in volunteers aged 55-85 years regardless of 
the applied dose. A Zn dose of 30 mg/day in the same 
subjects led to alterations in serum Fe and Cu status, 
which was not observed in the group with a lower 
zinc dose (25).
One limitation of this study was that it is focused 
on a relatively small number of subjects and was not 
a double-blind clinical trial. As we stated before, each 
patient signed informed consent that she/he will fol-
low study procedures, including the nutritionists’ rec-
ommendations. However, we are aware that patient 
compliance could also be a limitation of the present 
study. Therefore, it can be considered a pilot study in 
examining the efficacy of low doses zinc gluconate 
in patients with MG. In contrast to our study, Vahe-
di et al. (17) evaluated the therapeutic effect of zinc 
sulfate by recording only complete resolution of le-
sions. Furthermore, unlike in his study, we excluded 
subjects without subjective symptoms. In the litera-
ture, a 3-month period of zinc treatment was usually 
recommended as the therapy for dysgeusia (15), or 6 
months in case of BMS (14). We believe that 10 days 
without follow-up in a previous study (17) was not 
long enough to completely evaluate the treatment 
effects.
It would be desirable to determinate serum or 
saliva zinc levels before the supplementation treat-
ment, regardless of the fact that no association 
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between MG and salivary or serum zinc levels has 
been established (12). Therefore, we suggest further 
double-blind randomized studies on a larger sample 
over a longer period of treatment with follow-ups.
CONCLUSION
The results of the present study showed that a 
low dose of chelated zinc gluconate may have a posi-
tive therapeutic effect on the regeneration of tongue 
epithelium and significantly help alleviate subjective 
symptoms in patients with MG. In contrast, successful 
therapy only by a diet rich in zinc seems to be insuffi-
cient in patients with this condition. Regardless of the 
diet rich in zinc we recommend supplementation of 
about 3-5 mg/day of elemental zinc in subjects with 
MG.
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